eligibility_summary
Adults (≥18) with histologically proven CD30+ (>1%) lymphoma (HL, T‑NHL, CTCL, DLBCL) planned for brentuximab vedotin, measurable disease (CT lesion >1.5 cm and PET+), WHO PS 0–2, adequate liver, renal, and bone marrow function, Hb ≥8 g/dL, life expectancy >3 months, negative pregnancy test, consent. Exclude: hypersensitivity to BV/excipients/murine proteins, ≥grade 2 neuropathy, serious psych/medical/compliance issues, PET‑CT‑preventing claustrophobia, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Zirconium-89–labeled brentuximab vedotin (89Zr-BV) PET imaging, with/without small pre-doses of unlabeled brentuximab. Drug types/mechanisms: Brentuximab vedotin is an anti-CD30 IgG1 antibody–drug conjugate (ADC) linked to monomethyl auristatin E (MMAE), a microtubule inhibitor, after CD30 binding and internalization, MMAE is released to disrupt microtubules and induce apoptosis. 89Zr labeling turns the antibody into a PET radiotracer to quantify biodistribution, tumor uptake, and PK/PD. Targets: CD30 (TNFRSF8) on malignant B- and T-lymphocytes and CD30+ tumor microenvironment, downstream cytotoxic pathway is microtubule depolymerization. Imaging correlated with sCD30, CD30 IHC, and CD30 gene expression.